Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intracellular accumulation through silencing MATE1
Open Access
- 22 May 2020
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 117 (23), 13012-13022
- https://doi.org/10.1073/pnas.1918845117
Abstract
Metastatic colorectal cancer (mCRC) patients have poor overall survival despite using irinotecan- or oxaliplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) drugs, especially those with the oncogene mutation of KRAS. Metformin has been reported as a potentially novel antitumor agent in many experiments, but its therapeutic activity is discrepant and controversial so far. Inspiringly, the median survival time for KRAS-mutation mCRC patients with diabetes on metformin is 37.8 mo longer than those treated with other hypoglycemic drugs in combination with standard systemic therapy. In contrast, metformin could not improve the survival of mCRC patients with wild-type KRAS. Interestingly, metformin is preferentially accumulated in KRAS-mutation mCRC cells, but not wild-type ones, in both primary cell cultures and patient-derived xenografts, which is in agreement with its tremendous effect in KRAS-mutation mCRC. Mechanistically, the mutated KRAS oncoprotein hypermethylates and silences the expression of multidrug and toxic compound extrusion 1 (MATE1), a specific pump that expels metformin from the tumor cells by up-regulating DNA methyltransferase 1 (DNMT1). Our findings provide evidence that KRAS-mutation mCRC patients benefit from metformin treatment and targeting MATE1 may provide a strategy to improve the anticancer response of metformin.Keywords
This publication has 47 references indexed in Scilit:
- Diabetes, metformin use, and colorectal cancer survival in postmenopausal womenCancer Epidemiology, 2013
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal CancerThe New England Journal of Medicine, 2013
- K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValueISRN Molecular Biology, 2012
- Reduced Risk of Colorectal Cancer With Metformin Therapy in Patients With Type 2 DiabetesDiabetes Care, 2011
- Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancerBMC Cancer, 2010
- Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E contextMolecular Cancer, 2008
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- Critical roles of Sp1 in gene expression of human and rat H+/organic cation antiporter MATE1American Journal of Physiology-Renal Physiology, 2007
- The Akt-mTOR tango and its relevance to cancerCancer Cell, 2005
- 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapyOncogene, 2002